FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 339:924 September 24, 1998 Number 13 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Dighiero, G.

To the Editor: Dighiero et al. (May 21 issue)¹ conclude that the treatment of early-stage chronic lymphocytic leukemia (CLL) with alkylating agents not only is ineffective but also may adversely affect survival. This study confirms the long-held assumption that patients with early-stage disease should not be treated until there is evidence that the disease has progressed and that indiscriminate use of alkylating agents leads to an increased incidence of acute leukemia and epithelial cancers.

We were disappointed, though, by the statement in the discussion that secondary acute leukemia has not been reported in patients with CLL who are treated with . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.